Akebia Therapeutics Secures Up to $140 Million in New Financing, Eliminates BlackRock Debt and Strengthens Kidney Disease Strategy 

Akebia Therapeutics, a Massachusetts-based biopharmaceutical company specializing in kidney disease treatments, has announced a new financing agreement designed to strengthen its financial flexibility and support future business development. The company secured a $60 million senior secured loan from healthcare investment firm Symbiotic Capital, replacing an existing $55 million debt facility associated with BlackRock. Announced on […]